Companies: 10,795·Total market cap: $144.5T
Genmab A/S

Genmab A/S

GMABNASDAQHealthcare● Active
$25.15
+$0.42(+1.70%)
Market Cap$15.4B
P/E Ratio
52W High$35.43
52W Low$20.225

Genmab A/S (GMAB) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

gmab · stock forecast · 17 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 17 Wall Street analysts in the past 3 months

SellBuy

Buy

17 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
12
Hold
4
Sell
1
Strong Sell
0
Total: 17 · Buy rate: 70.6%

12-Month Price Target

High

$41.50

Consensus

$38.30

+52.3% upside

Low

$32.00

Median: $40 · Last Close: $25.15

The Genmab A/S (GMAB) analyst consensus is Buy, based on ratings from 17 Wall Street analysts over the past 3 months. The average 12-month GMAB price target is $38.30, representing +52.3% upside from the current price of $25.15.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $38 (52.3%)

Consensus Target

$38.30

52.3% upside

High Target

$41.5

65.0%

Low Target

$32

27.2%

Current Price

$25.15

as of today

Based on analyst price targets, the GMAB stock price prediction for the next 12 months ranges from $32 to $41.5. The consensus GMAB price forecast of $38.30 implies 52.3% upside from the current price of $25.15.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$24.144.00%

1-day model range: $24.04–$24.25. Peak: $24.25 (-4.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$24-5.9%
2028$23-9.6%
2029$22-11.8%
2030$22-13.3%
2031-14.2%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

14%7%79%
2Buy
1Neutral
11Sell
RSI (14)41.0Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · GMAB · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$24.61BUY
MA 10$25.69SELL
MA 20$26.15SELL
MA 50$26.89SELL
MA 100$28.35SELL
MA 200$29.26SELL
Current $GMAB · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$24.96BUY
EMA 10$25.41SELL
EMA 20$25.95SELL
EMA 50$26.80SELL
EMA 100$27.67SELL
EMA 200$27.70SELL
Current $GMAB · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2026-04-30
Maintains
BuyBuy
Guggenheim2026-02-23
Maintains
BuyBuy
HC Wainwright & Co.2026-02-18
Maintains
BuyBuy
HC Wainwright & Co.2026-01-28
Maintains
BuyBuy
HC Wainwright & Co.2026-01-20
Maintains
BuyBuy
HC Wainwright & Co.2025-11-10
Maintains
BuyBuy
Truist Securities2025-11-07
Maintains
BuyBuy
HC Wainwright & Co.2025-10-15
Maintains
BuyBuy
HC Wainwright & Co.2025-10-02
Maintains
BuyBuy
Guggenheim2025-09-24
Upgrade ↑
NeutralBuy

Wall Street analysts have recently issued updated ratings on Genmab A/S (GMAB) stock. Of the recent 131 rating actions, 8 were upgrades and 7 were downgrades. 17 analysts currently cover GMAB.

Analyst Recommendation Trends

Buy ratings211
Hold ratings00
Sell ratings00

GMAB analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$4.3B

↓ 29.0% YoY

Revenue Next Year

$5.1B

↑ 17.1% YoY

EPS This Year

$1.15

EPS Next Year

$1.67

↑ 45.3% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast GMAB EPS of $1.15 for the current fiscal year, based on estimates from 9 analysts. The GMAB revenue forecast is $4.3B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The GMAB stock forecast is supported by two independent data sources: analyst consensus ratings from 17 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GMAB price target is $38.30 (+52.3% upside), with an analyst consensus of Buy.

The GMAB short-term stock prediction for tomorrow is $24.14 (-4.00%). The GMAB stock price prediction for 2027 estimates an average of $24. The GMAB stock prediction for 2030 projects a range of $21–$23.

Genmab A/S trades on NASDAQ under the ticker GMAB. The GMAB stock outlook for 2027 is broadly positive, supported by a Buy consensus among 71% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

GMAB forecast · 8 questions

According to 17 Wall Street analysts, the average 12-month GMAB price target is $38.30, with a high forecast of $41.50 and a low of $32.00. The median price target is shown in the chart above when available. This implies +52.3% potential upside from the current price of $25.15.

GMAB price targetWhat is GMAB price targetGMAB analyst price targetGMAB 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.